SUPERNUS PHARMACEUTICALS, INC. Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss of -$47.00 thousand for the 9-month period ending 2015-09-30, per its 10-Q/A filed 2017-01-20.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2017-03-16
- SUPERNUS PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2015-09-30 was -$44.00K, a 222.22% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2015-06-30 was $86.00K.
- SUPERNUS PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2015-03-31 was -$89.00K.
- SUPERNUS PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2014-12-31 was $119.00K.
- SUPERNUS PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for fiscal 2014 was $154.00K.
- SUPERNUS PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for fiscal 2013 was -$57.00K, a 200.00% decline from fiscal 2012.
- SUPERNUS PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for fiscal 2012 was $57.00K.
- SUPERNUS PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for fiscal 2011 was -$1.00K, a 150.00% decline from fiscal 2010.
| Period end | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2015-09-30 | -$44.00K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-01-20 | $42.00K derived: sum of 2 quarters · filed 2017-01-20 | -$47.00K 10-Q/A · filed 2017-01-20 | $72.00K derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $86.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$3.00K 10-Q · filed 2015-08-07 | $116.00K derived: sum of 3 quarters · filed 2017-03-16 | $152.00K derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | -$89.00K 10-Q · filed 2015-05-06 | $30.00K derived: sum of 2 quarters · filed 2017-03-16 | $66.00K derived: sum of 3 quarters · filed 2017-03-16 | $66.00K derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | $119.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | $155.00K derived: sum of 2 quarters · filed 2017-03-16 | $155.00K derived: sum of 3 quarters · filed 2017-03-16 | $154.00K 10-K · filed 2017-03-16 |
| 2014-09-30 | $36.00K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-01-20 | $36.00K derived: sum of 2 quarters · filed 2017-01-20 | $35.00K 10-Q/A · filed 2017-01-20 | -$46.00K derived: sum of 4 quarters · filed 2017-01-20 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$1.00K 10-Q · filed 2015-08-07 | -$82.00K derived: sum of 3 quarters · filed 2017-01-20 | -$236.00K derived: sum of 4 quarters · filed 2017-01-20 |
| 2014-03-31 | -$1.00K 10-Q · filed 2015-05-06 | -$82.00K derived: sum of 2 quarters · filed 2017-01-20 | -$236.00K derived: sum of 3 quarters · filed 2017-01-20 | -$90.00K derived: sum of 4 quarters · filed 2017-01-20 |
| 2013-12-31 | -$81.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-01-20 | -$235.00K derived: sum of 2 quarters · filed 2017-01-20 | -$89.00K derived: sum of 3 quarters · filed 2017-01-20 | -$57.00K 10-K/A · filed 2017-01-20 |
| 2013-09-30 | -$154.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$8.00K derived: sum of 2 quarters · filed 2014-11-12 | $24.00K 10-Q · filed 2014-11-12 | $52.00K derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | $146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $178.00K 10-Q · filed 2014-08-12 | $206.00K derived: sum of 3 quarters · filed 2015-03-12 | $241.00K derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | $32.00K 10-Q · filed 2014-05-13 | $60.00K derived: sum of 2 quarters · filed 2015-03-12 | $95.00K derived: sum of 3 quarters · filed 2015-03-12 | $97.00K derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $63.00K derived: sum of 2 quarters · filed 2015-03-12 | $65.00K derived: sum of 3 quarters · filed 2015-03-12 | $57.00K 10-K · filed 2015-03-12 |
| 2012-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $37.00K derived: sum of 2 quarters · filed 2013-11-13 | $29.00K 10-Q · filed 2013-11-13 | $29.00K derived: sum of 4 quarters · filed 2014-03-21 |
| 2012-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | -$6.00K 10-Q · filed 2013-08-14 | -$6.00K derived: sum of 3 quarters · filed 2014-03-21 | -$5.00K derived: sum of 4 quarters · filed 2014-03-21 |
| 2012-03-31 | -$8.00K 10-Q · filed 2013-05-15 | -$8.00K derived: sum of 2 quarters · filed 2014-03-21 | -$7.00K derived: sum of 3 quarters · filed 2014-03-21 | -$7.00K derived: sum of 4 quarters · filed 2014-03-21 |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | $1.00K derived: sum of 2 quarters · filed 2014-03-21 | $1.00K derived: sum of 3 quarters · filed 2014-03-21 | -$1.00K 10-K · filed 2014-03-21 |
| 2011-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | $1.00K derived: sum of 2 quarters · filed 2012-11-02 | -$1.00K 10-Q · filed 2012-11-02 | |
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | -$2.00K 10-Q · filed 2012-08-13 | ||
| 2011-03-31 | -$2.00K 10-Q · filed 2012-06-08 | |||
| 2010-12-31 | $2.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |